Buscar
Akero Therapeutics Inc
AKROAñadir a la lista de seguimiento
54.650USD
0.0000.00%
Cierre 06/26, 16:00（ET）Cotizaciones retrasadas 15 min
4.50BCap. mercado
PérdidaP/E TTM
Más Datos de Akero Therapeutics Inc Compañía
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Información de Akero Therapeutics Inc
Símbolo de cotizaciónAKRO
Nombre de la empresaAkero Therapeutics Inc
Fecha de salida a bolsaJun 20, 2019
Director ejecutivoCheng (Andrew)
Número de empleados63
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 20
Dirección601 Gateway Boulevard, Suite 350
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504876488
Sitio Webhttps://akerotx.com/
Símbolo de cotizaciónAKRO
Fecha de salida a bolsaJun 20, 2019
Director ejecutivoCheng (Andrew)
Ejecutivos de Akero Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-29.36%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+23.27%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-965.84%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Pritchett Henderson
Ms. Jane Pritchett Henderson
Independent Director
Independent Director
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-29.36%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+23.27%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-965.84%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Akero Therapeutics Inc?
Los cinco principales accionistas de Akero Therapeutics Inc son: Dr. Andrew Cheng, M.D., Ph.D.
¿Cuántas instituciones poseen acciones de Akero Therapeutics Inc (AKRO)?
A fecha de 2026Q1, 499 instituciones poseen acciones de Akero Therapeutics Inc, con un valor de mercado combinado de aproximadamente 491.95K, lo que representa el 0.60% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -100921305.00.
